Sodium Phenylbutyrate

Sodium phenylbutyrate affects glutamine depletion and cell differentiation in cancer cells, as shown in cancer research studies.

Sodium phenylbutyrate (SPB) as a salt of 4-phenylbutyric acid (4-PBA) has been reported to be an ammonia scavenger, histone deacetylase inhibitor, and endoplasmic reticulum stress inhibitor in various diseases, including neurological diseases, inflammatory disorders, and carcinogenesis. Since the early 1990s, sodium phenylbutyrate has been used in clinical studies worldwide. The results of these studies are extremely promising.


Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery.

Scroll to Top